Levact: new blood cancer drug

Levact: a new chemotherapy agent
Levact: a new chemotherapy agent

Bendamustine is an alkylating antitumour agent with unique activity.1 It is licenced for use:

  • in the first-line treatment of chronic lymphocytic leukaemia (Binet stage B or C) when fludarabine combination chemotherapy is not appropriate.
  • as monotherapy for indolent non-Hodgkin’s lymphoma that has progressed during or within 6 months of rituximab treatment.
  • in combination with prednisone for multiple myeloma (Durie-Salmon stage II with progress or stage III) in patients >65 years who are not eligible for autologous stem cell transplantation, thalidomide or bortezomib.

The drug’s antineoplastic and cytocidal effects are based on the cross-linking of DNA single and double strands by alkylation, which results in impaired DNA synthesis and repair.

Clinical studies have shown that there is no complete cross-resistance of bendamustine with anthracyclines, alkylating agents or rituximab, however, the number of assessed patients was small.1

View Levact drug record

REFERENCES

  1. Levact Summary of Product Characteristics, August 2010.

Further information: Napp

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more